Skip Navigation LinksInfantBotulism

Infant Botulism TREATMENT AND PREVENTION PROGRAM

The mission of the IBTPP is to provide and improve the treatment of infant botulism and to prevent infant botulism and related diseases. 

BabyBIG® Packaging
Gram Stain Clostridiumbotulinum
BabyBIG® Information and OrderingLaboratory and Diagnostic Info

Please click on photos above for more information about how to obtain BabyBIG®, consultation for suspected infant botulism, and laboratory testing in California.

Also visit our infant botulism main page for in-depth information.

What is infant botulism? Infant botulism is an orphan ("rare") disease that affects infants under 1 year of age. First recognized in 1976, infant botulism occurs globally and is the most common form of human botulism in the United States.

BabyBIG®, Botulism Immune Globulin Intravenous (Human) (BIG-IV) is an orphan drug that consists of human-derived anti-botulism toxin antibodies that is approved by the U.S. Food and Drug Administration for the treatment of infant botulism type A and type B. 

Contact us by phone, fax, or email:

Phone: Physicians with a suspected case of infant botulism may reach our program at (510) 231-7600 (24/7/365). However, if you are a parent with concerns or questions about suspected infant botulism, please contact your pediatrician.

Email: If you have non-urgent questions or comments, please email the program at: IBTPP@infantbotulism.org ​​

Fax: (510) 231-7609

For more in-depth information, please visit our infant botulism main page.

Page Last Updated :